The increasing prevalence of thrombocytopenia, rising incidence of immune thrombocytopenia (ITP), aplastic anemia, and chemotherapy-induced thrombocytopenia are driving demand for thrombopoietin receptor agonists worldwide. However, the market also faces several challenges. High treatment costs, stringent regulatory approval requirements, and limited patient access in developing...